Keunggulan tirzepatide milik Lilly dibandingkan dengan plasebo untuk penyelesaian MASH, dan lebih dari setengah pasien mencapai perbaikan dalam fibrosis pada 52 minggu

Zepbound. Talk to your healthcare provider for more information.

Please see the full Prescribing Information, including Medication Guide, for Zepbound at www.zepbound.com.

About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/news.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about tirzepatide as a potential treatment for people with MASH and reflects

MEMBACA  Skotlandia, Bergabung dengan Inggris dan Wales, Akan Membatasi Anjing XL yang Mengganggu